433728-71-3Relevant academic research and scientific papers
METHODS AND COMPOSITIONS OF PARP INHIBITORS AS POTENTIATORS IN CANCER THERAPY
-
Page/Page column 33, (2008/06/13)
The present disclosure relates generally to a series of compounds which are derivatives of tricyclic compounds which inhibit poly (ADP-ribose) polymerase (PARP) and their use in the potentiation of cancer therapies. The disclosure relates more particularl
Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries
Ferraris, Dana,Ko, Yao-Sen,Pahutski, Thomas,Ficco, Rica Pargas,Serdyuk, Larisa,Alemu, Christina,Bradford, Chadwick,Chiou, Tiffany,Hoover, Randall,Huang, Shirley,Lautar, Susan,Liang, Shi,Lin, Qian,Lu, May X.-C.,Mooney, Maria,Morgan, Lisa,Qian, Yongzhen,Tran, Scott,Williams, Lawrence R.,Wu, Qi Yi,Zhang, Jie,Zou, Yinong,Kalish, Vincent
, p. 3138 - 3151 (2007/10/03)
A series of aza-5[H]-phenanthridin-6-ones were synthesized and evaluated as inhibitors of poly ADP-ribose polymerase-1 (PARP-1). Inhibitory potency of the unsubstituted aza-5[H]-phenanthridin-6-ones (i.e., benzonaphthyridones) was dependent on the positio
